Our Clinical Trials

AML

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the FLT3 Inhibitor Gilteritinib (ASP2215) Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects with FLT3/ITD AML in First Complete Remission.

A Phase 1 Dose Escalation Trial of SKI-G-801 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML).

A Randomized, Open-Label Study of the Efficacy and Safety of Galinpepimut-S (GPS) Maintenance Monotherapy Compared to Investigator's Choice of Best Available Therapy in Subjects with Acute Myeloid Leukemia Who Have Achieved Complete Remission After Second-Line Salvage Therapy

A Phase 1 Dose Escalation Trial of SKI-G-801 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) (Opened 3/07/2018) (SKI-G-801 will be provided by the sponsor)

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Compare Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Subjects with Acute Myloid Leukemia in Complete Remission.

A Phase IIb, randomized, double-blind, placebo-controlled, low-dose cytarabine and Lintuzumab In comparison with the low-dose cytarabine and placebo in patients 60 years of age and older with previously untreated AML.


Biomarker Expression

A Registry of Caris Target Now Test Results (Biomarker Expression Patterns) and Hematopoietic Diagnostics for Evaluation of Correlation with Clinical Outcomes for Cancer and Other Patients.


Bladder

An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects with Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301), 2nd/3rd line.

A Phase 2 Open Label Study of IMMU-132

A Phase 1 Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination with Tremelimumab (Anti-CTLA-4 Antibody) in Subjects with Advanced Solid Bladder Tumors.

A Phase 2 Open Label Study of IMMU-132 in Metastatic Urothelial Cancer after Failure of Platinum-Based Regimen or Anti-PD-1 Based Immunotherapy, 2nd/3rd line.

An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects with Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301). 2nd/3rd LINE

Blood Sample Collection to Evaluate Biomakers in Subjects with Untreated Solid Tumors, 1st line.

An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects with Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301). 2nd/3rd LINE

A Phase 2 Open-Label Study of IMMU-132 in Metastatic Urothelial Cancer after Failure of Platinum-Based Regimen or Anti-PD-1 Based Immunotherapy.

Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated Solid Tumors, 1st LINE.

A Phase 2, Open-Label Study of NKTR-214 in Combination with Nivolumab in Cisplatin Ineligible, Locally Advanced or Metastatic Urothelial Cancer, 1st LINE.

A Phase 2, Open-Label Study to Evaluate Safety And Clinical Activity of Avelumab (Bavencio) In Combination With Acitinib (Inlyta) in patients with advanced or metastatic previously treated Non-Small Cell Lung Cancer or Treatment-Naive Cisplatin Ineligible Urothelial Cancer, 1st LINE.

An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects with Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301), 2nd/3rd LINE.

A Phase 2 Open-Label Study of IMMU-132 in Metastatic Urothelial Cancer after Failure of Platinum-Based Regimen or Anti-PD-1 Based Immunotherapy, 2nd/3rd LINE.

A Phase 2 Open Label Study of IMMU-132 in Metastatic Urothelial Cancer after Failure of Platinum-Based Regimen or Anti-PD-1 Based Immunotherapy. 

Blood Sample Collection to Evaluate Biomakers in Subjects with Untreated Solid Tumors, 1st line.

A Phase 2, Open Label Study of NKTR-214

A Phase 2, Open Label Study of NKTR-214 in Combination with Nivolumab in Cisplatin Ineligible, Locally Advanced or Metastatic Urothelial Cancer, 1st line.

An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy


Breast

A Phase 3, Open-Label, Randomized, Parallel, 2-Arm, Multi-Center Study of Talazoparib (BMN 673) versus Physician’s Choice in Germline BRCA Mutation Subjects with Locally advanced and/or Metastatic Breast Cancer, Who Have Received Prior Chemotherapy Regimens for Metastatic Disease

A Randomized, Multicenter, Open-Label Cross-Over Study to Evaluate Patients Preference and Satisfaction of Subcutaneous Administration of The Fixed-Dose Combination of Pertuzumab and Trastuzumab in Patients with Her 2 Positive Early Breast Cancer, 1ST LINE.

A Phase 3, multicenter, randomized, open-label, active-controlled study of DS-8201a, an anti-HER2-antibody drug conjugate, versus ado-trastuzumab emtansine (T-DM1) for HER2-positive, unresectable and/or metastatic breast cancer subjects previously treated with trastuzumab and taxane, 1st line.

A Phase 1b/2 Study of Eribulin Mesylate in Combination with PEGylated Recombinant Human Hyaluronidase (PEGPH20) versus Eribulin Mesylate Alone in Subjects with Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)

Treatment-Resistant Following Anti-Cancer Therapies.

A Phase 2 MuLticenter, Open-label Study of Rucaparib as Treatment for SoliD Tumors Associated with DEleteriouS MuTations in Homologous RecombinAtion Repair Genes

A Phase 2 Study of Imprime PGG and Pembrolizumab MK3475 PN-545 in Subjects With Advanced Melanoma Failing Front-line Treatment with Checkpoint Inhibitors (CPI) or Triple Negative Breast Cancer (TNBC) Failing Front-line Chemotherapy for Metastatic Disease.

A Randomized, Multicenter, Open-Label Cross-Over Study to Evaluate Patients Preference and Satisfaction of Subcutaneous Administration of The Fixed-Dose Combination of Pertuzumab and Trastuzumab in Patients with Her 2 Positive Early Breast Cancer, 1st Line.

A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-line

Treatment for Patients with Histologically Confirmed, Locally Advanced(Inoperable) or Metastatic Triple-Negative Breast Cancer (TNBC)

A Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients with Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy.

A phase 1/2 Study of Galinpepimut-s SLS17-201 A phase 1/2 Study of Galinpepimut-s in Combination with Pembrolizumab (MK-3475) in Patients with Selected Advanced Cancers, 2nd line.

Open-label, multicentre, Phase Ib dose-escalation study of MEN1611, a PI3K inhibitor combined with trastuzumab ± fulvestrant, in subjects with PIK3CA mutated HER2-positive locally recurrent unresectable (advanced) or metastatic (a/m) breast cancer progressed to anti-HER2 based therapy

A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Who are Resistant or Refractory to T-DM1.

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane, 1ST– 2nd line metastatic.

A Phase 2 MuLticenter, Open-label Study of Rucaparib as Treatment for SoliD Tumors Associated with DEleteriouS MuTations in Homologous RecombinAtion Repair Genes.

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane- 1st- 2nd line metastatic.

A Randomized, Multicenter, Open-Label Cross-Over Study to Evaluate Patients Preference and Satisfaction of Subcutaneous Administration of The Fixed-Dose Combination of Pertuzumab and Trastuzumab.

A Phase 3,Multicenter Randomized Open-Label ,Active-Controlled Study of DS-8201A, an anti-Her 2 Antibody Drug Conjugate, Versus Treatment of Investigator's Choice for Her 2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Pretreated with Prior Standard of Care Her 2 Therapies, Including T-DMI

Monotherapy in the Treatment of HER2-ve Metastatic Breast Cancer- 1st- 2nd line metastatic.

A Randomized, Multicenter, Open-Label Cross-Over Study to Evaluate Patients Preference and Satisfaction of Subcutaneous Administration of The Fixed-Dose Combination of Pertuzumab and Trastuzumab in Patients with Her 2 Positive Early Breast Cancer, 1ST line.

A Phase 2 MuLticenter, Open-label Study of Rucaparib as Treatment for SoliD Tumors Associated with DEleteriouS MuTations in Homologous RecombinAtion Repair Genes.

A Randomized, Multicenter, Open-Label Cross-Over Study to Evaluate Patients Preference and Satisfaction of Subcutaneous Administration of The Fixed-Dose Combination of Pertuzumab and Trastuzumab in Patients with Her 2 Positive Early Breast Cancer.

A Study of Patients with Germline BRCA1/2 Mutations - 1st- 2nd line metastatic.

A Randomized, Multicenter, Open-Label Cross-Over Study to Evaluate Patients Preference and Satisfaction of Subcutaneous Administration of The Fixed-Dose Combination of Pertuzumab and Trastuzumab in Patients with Her 2 Positive Early Breast Cancer, 1ST line.

A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Fulvestrant Versus Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2−) Breast Cancer Following Recurrence or Progression On or After Treatment with an Aromatase Inhibitor

A Phase 3 Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the PARP Inhibitor Veliparib (ABT-888) in HER2-Negative Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer.

A multicenter, randomized, double-blind, double-dummy, active-controlled, parallel group phase 3b study to assess the safety and to describe the efficacy of IV fosnetupitant/palonosetron combination compared to oral netupitant/palonosetron combination for the prevention ofchemotherapy-induced nausea and vomiting in initial and repeated cycles of anthracycline-cyclophosphamide chemotherapy in women with 1ST LINE METASTATIC breast cancer.

Blood Sample Collection to Evaluate Biomakers in Subjects with Untreated Solid Tumors, 1st line.

A Randomized, Non-comparative, Neoadjuvant, Phase 2 study in patients with ER+/HER2- Breast Cancer  more than or equal to 2 cm with Safety Run-in, Assessing Nivolumab + Abemaciclib or Palbociclib + Anastrozole

A Phase II, An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients with Early-Stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis.

A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Monotherapy in the Treatment of HER2-ve Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutations

Treatment Resistant Following Anti-Cancer Therapies, 1st line.

A Multinational, Multicenter, Phase 2 Study of Tesetaxel plus a Reduced Dose of Capecitabine in Patients with HER2 Negative,Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Received a Taxane.

A Randomized Trial of SPI-2012 Versus Pegfilgrastim in the Management of Chemotherapy Induced Neutropenia in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide.

Monotherapy in the Treatment of HER2-ve Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutations.

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone

A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer.

Phase 2 Study of Poziotinib in Patients with HER2-Positive Metastatic Breast Cancer (MBC) who have received prior HER2 Regimens for MBC.

A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC).

A Multinational, Multicenter, Phase 2 Study of Tesetaxel plus a Reduced Dose of Capecitabine in Patients with HER2 Negative,Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Received a Taxane, 1ST– 2nd line metastatic.

Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Fulvestrant Versus Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2−) Breast Cancer Following Recurrence or Progression On or After Treatment with an Aromatase Inhibitor 

A Phase 3, Open-Label, Randomized, Parallel, 2-Arm, Multi-Center Study of Talazoparib (BMN 673) versus Physician’s Choice in Germline BRCA Mutation Subjects with Locally advanced and/or Metastatic Breast Cancer, Who Have Received Prior Chemotherapy Regimens for Metastatic Disease.

A Phase 2/3, Multicenter, Randomized, Double Blind, Study to Evaluate Duration of Severe Neutropenia with Plinabulin Versus Pegfilgrastim

A Randomized, Multicenter, Open-Label Cross-Over Study to Evaluate Patients Preference and Satisfaction of Subcutaneous Administration

A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-line Treatment for Patients with Histologically Confirmed, Locally Advanced (Inoperable) or Metastatic Triple-Negative Breast Cancer (TNBC)

A Randomized, Double-Blind, Phase III Study of Pembrolizumab (MK-3475) plus Chemotherapy vs Placebo plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer.

A Phase 2/3, Multicenter, Randomized, Double Blind, Study to Evaluate Duration of Severe Neutropenia with Plinabulin Versus Pegfilgrastim in Patients with Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy. ADJUVANT/NEOADJUVANT/1ST LINE METASTATIC.

A Randomized, Multicenter, Open-Label Cross-Over Study to Evaluate Patients Preference and Satisfaction of Subcutaneous Administration of The Fixed-Dose Combination of Pertuzumab and Trastuzumab in Patients with Her 2 Positive Early Breast Cancer, 1st line.

Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Fulvestrant Versus Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2−) Breast Cancer Following Recurrence or Progression On or After Treatment with an Aromatase Inhibitor 

A Phase 3, Multicenter Randomized Open-Label,Active-Controlled Study of DS-8201A, an anti-Her 2 Antibody Drug Conjugate, Versus Treatment of Investigator's Choice for Her 2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Pretreated with Prior Standard of Care Her 2 Therapies, Including T-DMI, 2nd LINE METASTATIC.

Blood Sample Collection to Evaluate Biomakers in Subjects with Untreated Solid Tumors, 1st LINE.

A Phase 3, multicenter, randomized, open-label, active-controlled study of DS-8201a

Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients with HER2+ Metastatic Breast Cancer who have Received Two or More Prior HER2-Directed Regimens in the Metastatic Setting (NALA)

A Multinational, Multicenter, Phase 2 Study of Tesetaxel

Study is for germline mutated BRCA (gBRCAm), HER2 -ve breast cancer with PD on a PARP inhibitor monotherapy in patients previously treated with chemotherapy in neoadjuvant, adjuvant, or metastatic setting.

Randomized phase II neoadjuvant trastuzumab and / or lapatinib plus chemotherapy (sequential FEC75 and paclitaxel) in women with ErbB2 (HER2) overexpressinginvasive breast cancer trial.

A Phase III, randomized, open-label Versus Neratinib lapatinib plus capecitabine for the treatment of ErbB-2 positive metastatic or locally advanced breast cancer.

A phase III randomized, double-blind, controlled trial with placebo to evaluate the efficacy and safety of pertuzumab plus trastuzumab + docetaxel vs. Placebo + trastuzumab + docetaxel in HER2-positive breast cancer previously untreated metastatic.

A multicenter, international study open - label, two-arm, Phase III trial of Avastin in adjuvant "triple negative" breast cancer.

Randomized phase III study of sunitinib in combination with capecitabine compared with capecitabine in breast cancer patients previously treated Or metastatic An international, randomized, double-blind, placebo-controlled, Phase II AMG 479 with exemestane or fulvestrant in postmenopausal women with hormone receptor positive breast cancer locally advanced: • randomized studies evaluating AMG 479.

An observational study of treatment patterns of the results of safety metastatic or locally advanced breast cancer.

A randomized, multicenter, phase III open-label study of the efficacy and safety of trastuzumab-MCC-DM1 VS. Lapatinib and capecitabine in patients with HER2-positive breast cancer locally advanced or metastatic who have received prior trastuzumab-based therapy.

A prospective, randomized, double-blind, stratified, multi-Trial 2 arms of the continued efficacy and safety of Zometa ® (every 4 weeks versus every 12 weeks) in patients with documented bone metastases from breast cancer.

A phase II, randomized, open-label bosutinib administered in combination with letrozole versus letrozole alone as first-line therapy in postmenopausal women with locally advanced or metastatic ER + / PGR + / erbB2- Breast Cancer.

An observational study of treatment patterns and safety outcomes for metastatic breast cancer or locally recurrent.

A phase II, double-blind, randomized, placebo-controlled study of ACE-011 for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer.

A Phase II, multicenter, open-label, randomized study of YM155 and docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer protocol for the Phase II of YM155.

A, open, randomized, phase III taxane based chemotherapy with lapatinib and trastuzumab as first-line treatment for women with metastatic breast cancer HER2 / neu positive.

A, 3 randomized, multicenter, phase III study to evaluate the efficacy and safety of T-DM1 combined with pertuzumab and T-DM1 combined with pertuzumab-placebo (blinded for pertuzumab) arm, versus Herceptin plus-taxane combination as first-line therapy in progressive or recurrent breast cancer locally advanced or metastatic HER2-positive (MBC).

A Phase 1/2 study to evaluate the safety, tolerability and preliminary efficacy of KW-2450 in combination with letrozole and lapatinib in patients with advanced or metastatic breast cancer whose tumors overexpress HER2.

Observational cohort study of treatment patterns and outcomes in patients with HER2 positive (HER2 +) metastatic breast cancer.

A study of more Neratinib capecitabine versus lapatinib plus capecitabine in patients with HER2 + HER2 + metastatic cancer who have received two or more HER2-Directed regimes earlier in metastatic disease (NALA).

Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients with HER2+ Metastatic Breast Cancer who have Received Two or More Prior HER2-Directed Regimens in the Metastatic Setting (NALA).

A Phase 2, Multicenter, open-label study to Assess the Efficacy and Safety of Enzalutamide with Trastuzumab in Subjects with HER2+ AR+ Metastatic or Locally Advanced Breast Cancer.

Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the PARP Inhibitor Veliparib (ABT-888) in HER2-Negative Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer.

A Phase II, An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients with Early-Stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis.


CLL

A Multi-Center, Open-Label, Study to Evaluate the Safety and Efficacy of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304.

A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy.

Screening Protocol to Determine High-risk Cytogenetic Features in Patients with Previously-treated CLL that may be Eligible for TG Therapeutics Trial UTX-IB-301.

A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia

A Multi-Center, Open-Label, Study to Evaluate the Safety and Efficacy of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304

A Phase II, Single Arm, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of MOR00208 Combined with Idelalisib in Patients with Relapsed or Refractory CLL/SLL Previously Treated with Bruton’s Tyrosine Kinase (BTK) Inhibitor

A Phase 1, Dose-Escalation and Cohort Expansion Study

A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects with Chronic Lymphocytic Leukemia

A Phase III, multicenter, randomized, open, parallel-group study of the efficacy and safety of lenalidomide (Revlimid ®) versus chlorambucil as first-line treatment for elderly patients treated Mobile B- previously with chronic lymphocytic leukemia

A Phase 2, Single Arm Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia with 17p Deletion

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

A Phase III Randomized, Study to Assess the Efficacy and Safety of Ublituximab in Combination with Ibrutinib Compared to Ibrutinib Alone, in Patients with Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)


CML

A Two-Part Phase 1/2 Study to Determine Safety, Tolerability, Pharmacokinetics, and Activity of K0706, a Novel Tyrosine Kinase Inhibitor (TKI), in Healthy Subjects and in Subjects with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL).

A phase 1/2 Study of Galinpepimut-s in Combination with Pembrolizumab (MK-3475) in Patients with Selected Advanced Cancers 2nd line.

A Two-Part Phase 1/2 Study to Determine Safety, Tolerability, Pharmacokinetics, and Activity of K0706, a Novel Tyrosine Kinase Inhibitor (TKI), in Healthy/ Subjects and in Subjects with Chronic Myeloid Leukemia (CM/L) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL).diagnosed with Ph+ CML-CP, Ph+ CML-AP, Ph+ CML-BP, or Ph+ ALL who are refractory or intolerant to at least 3 TKIs. (Opened 8/18/2017)  (K0706 and Placebo is provided by the trial)

An open label, randomized (2:1) Phase 2B study of Dasatinib vs Imatinib in patients with chronic phase chronic myeloid leukemia who have not achieved an optimal response to 3 months of therapy with 400 mg imatinib


Colorectal

Blood Sample Collection to Evaluate Biomakers in Subjects with Untreated Solid Tumors, 1st LINE.

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-033, an Anti-LAG-3 Monoclonal Antibody, Alone and in Combination With an Anti-PD-1 in Patients With Advanced Solid Tumors

A Phase 2 MuLticenter, Open-label Study of Rucaparib as Treatment for SoliD Tumors Associated with DEleteriouS MuTations in Homologous RecombinAtion Repair Genes

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-033, an Anti-LAG-3 Monoclonal Antibody, Alone and in Combination With an Anti-PD-1 in Patients With Advanced Solid Tumors

Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated Solid Tumors, 1st LINE.

A phase 1/2 Study of Galinpepimut-s in Combination with Pembrolizumab (MK-3475) in Patients with Selected Advanced Cancers, 3rd/4th line.

Blood Sample Collection to Evaluate Biomakers in Subjects with Untreated Solid Tumors, 1st line.

A multicenter, open-label, randomized, phase II study to evaluate the efficacy and safety of NKTR-102 (PEG-irinotecan) versus irinotecan in patients with second line, irinotecan- Naïve, -mutante KRAS metastatic colorectal cancer (mCRC)

Phase 1b / 2 Study of AMG 655 in combination with modified FOLFOX6 and bevacizumab for the first-line treatment of patients with metastatic colorectal cancer.

Locally advanced observational study of Bevacizumab (Avastin) in combination with chemotherapy for the treatment of metastatic colorectal cancer or locally advanced unresectable or metastatic non-small cell lung metastatic (except predominant histology squamous) cells. Locally advanced or metastatic CRC unresectable locally advanced or metastatic NSCLC

A Randomized Phase 2 Study 7 on / 7 capecitabine in combination with irinotecan or oxaliplatin short duration and bevacizumab either short-lived as first-line treatment for patients with metastatic colorectal cancer.

Comparison of the performance of the Epi proColon test and fecal immunochemical Post colonoscopy in patients with colorectal cancer and colonoscopy in subjects Pre-Eligible Population Screening Guidance.

A Phase 3 open-label, randomized, multicenter Print PGG ® in combination with cetuximab (Erbitux ®) in patients with recurrent or progressive type KRAS colorectal cancer Wild.

A Phase III, multicenter, open, randomized, pivotal trial of Vera MABp1 ™ human monoclonal antibody in patients with metastatic colorectal cancer who are refractory to standard therapy.


Gastrointestinal

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5745 Combined with mFOLFOX6 as First Line Treatment in Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.

A Phase 1/3 Study of FPA144 versus Placebo in Combination with Modified FOLFOX6 in Patients with Previously Untreated Advanced Gastric and Gastroesophageal Cancer.

Blood Sample Collection to Evaluate Biomakers in Subjects with Untreated Solid Tumors.

Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated Solid Tumors, 1ST LINE OR GREATER METASTATIC.

A Phase 2 MuLticenter, Open-label Study of Rucaparib as Treatment for SoliD Tumors Associated with DEleteriouS MuTations in Homologous RecombinAtion Repair Genes

A Phase 1/3 Study of FPA144 versus Placebo in Combination with Modified FOLFOX6

A Phase 1/3 Study of FPA144 versus Placebo in Combination with Modified FOLFOX6 in Patients with Previously Untreated Advanced Gastric and Gastroesophageal Cancer, 1ST line or greater metastatic.

Blood Sample Collection to Evaluate Biomakers in Subjects with Untreated Solid Tumors, 1ST line or greater metastatic.

A double-blind, randomized, multicenter Phase III study of Avastin in combination with capecitabine and cisplatin versus placebo in combination with capecitabine and cisplatin as first-line treatment in patients with advanced gastric cancer.

A database of observation to obtain data on variations in the current diagnostic and therapeutic management of patients with GIST in a variety of practice areas.

A randomized, open-label, multicenter Phase IIIb Comparison study of two dosage regimens Trastuzumab, each in combination with cisplatin / capecitabine chemotherapy as first-line treatment in patients with HER2-positive metastatic gastric or Gastro Junction Adenocarcinoma -esofágico who have not received prior treatment for metastatic disease.


HCC

A Multicenter, Single Arm, Phase Ib/II Study to Evaluate Efficacy, Safety, and PK of MSC2156119J as Monotherapy in Subjects with MET+ Advanced Hepatocellular Carcinoma with Child Pugh Class A Liver Function Who Have Failed Sorafenib Treatment.

A Multicenter, Single Arm, Phase Ib/II Study to Evaluate Efficacy, Safety, and PK of MSC2156119J as Monotherapy in Subjects with MET+ Advanced Hepatocellular Carcinoma with Child Pugh Class A Liver Function Who Have Failed Sorafenib Treatment.


Head and Neck

An Open-Label, Phase 2, Parallel Arm Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 Single Agent in Patients with Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors, 2ND line.

A Phase 2 MuLticenter, Open-label Study of Rucaparib as Treatment for SoliD Tumors Associated with DEleteriouS MuTations in Homologous RecombinAtion Repair Genes.

Blood Sample Collection to Evaluate Biomakers in Subjects with Untreated Solid Tumors, 1st line.

An Open-Label, Phase 2, Parallel Arm Study to Evaluate the Safety, Tolerability, and Activity of TAK-931

An Open-Label, Phase 2, Parallel Arm Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 Single Agent in Patients With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors, 2nd line.

Reduction in Oral Mucositis with Avaspasem

Blood Sample Collection to Evaluate Biomakers in Subjects with Untreated Solid Tumors.

Reduction in Oral Mucositis with Avaspasem Manganese (GC4419)-Phase 3 Trial in Patients Receiving Chemotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer, 1st line locally advanced.

A Randomized Double-Blind Phase 3 Study of Avelumab in Combination with Standard of Care Chemoradiotherapy (Cisplatin plus Definitive Radiation therapy) versus Standard of Care Chemoradiotherapy in the Front-Line treatment of Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck.

A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients with Head and Neck Squamous Cell Carcinoma ( HNSCC) with HRAS Mutation (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC (SEQ-HN). Hypersensitivity to platinum

ROMAN: Reduction in Oral Mucositis with Avaspasem Manganese (GC4419)-Phase 3 Trial in Patients Receiving Chemotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer.

A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients with Head and Neck Squamous Cell Carcinoma ( HNSCC) with HRAS Mutation (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC (SEQ-HN), 2nd LINE.

A 2 Cohort, Non-comparative, Pivotal Study Evaluating KURA KO-TIP-007

An Open-Label, Phase 2, Parallel Arm Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 Single Agent in Patients With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors, 1st LINE.

An Open-Label, Phase 2, Parallel Arm Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 Single Agent in Patients With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors, 2nd LINE.

Reduction in Oral Mucositis with Avaspasem Manganese (GC4419)-Phase 3 Trial in Patients Receiving Chemotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer, 1st LINE LOCALLY ADVANCED.

An Open-Label, Phase 2, Parallel Arm Study to Evaluate the Safety, Tolerability, and Activity of TAK-931

A randomized, double-blind, Phase 2 study of cetuximab safety, ImClone against Boehringer Ingelheim With manufacturing processes, in combination with cisplatin or carboplatin and 5-fluorouracil in the first-line treatment of patients with recurrent locoregional and / or metastatic squamous cell carcinoma of head and neck.

A multi-center, single-arm, global, Phase II study to determine the efficacy and safety of MEDI4736 monotherapy in the treatment of patients with recurrent or metastatic PD-L1-positive squamous cell carcinoma of the head and neck (SCCHN) who have progressed during or after treatment with a platinum-containing regimen for recurrent or metastatic disease.

A Phase II, Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy, Tremelimumab Monotherapy, and MEDI4736 in Combination with Tremelimumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN).

A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy and MEDI4736 in combination with Tremelimumab vs Standard of Care Therapy in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck.


Hematology

Efficacy and Safety of M281 in Adults with Warm Autoimmune Hemolytic Anemia: A  Multicenter, Randomized, Double-blind, Placebo-controlled Study

A Two-Part Phase 1/2 Study to Determine Safety, Tolerability, Pharmacokinetics, and Activity of K0706

A Randomized, Double-blind, Active-controlled, Phase 3 Study Evaluating the Efficacy and Safety of ABP 959

A Phase 3, Randomized Double-Blind Placebo-Controlled Study, Investigating the Efficacy and Safety of Roxadustat for treatment of Anemia in Patients with Lower Risk Myelodysplastic Syndrome with Low Red Blood Cell (RBC) Transfusion Burden (LTB).

A Two-Part Phase 1/2 Study to Determine Safety, Tolerability, Pharmacokinetics, and Activity of K0706, a Novel Tyrosine Kinase Inhibitor (TKI), in Healthy/ Subjects and in Subjects with Chronic Myeloid Leukemia (CM/L) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL), 4th line.

A Randomized, Double-blind, Active-controlled, Phase 3 Study Evaluating the Efficacy and Safety of ABP 959 Compared With Eculizumab in Adult Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH).

A Phase 2b Study to Evaluate the Safety and Efficacy of IMR-687 in Subjects with Sickle Cell Disease

A Randomized, Double-blind, Active-controlled, Phase 3 Study Evaluating the Efficacy and Safety of ABP 959 Compared With Eculizumab in Adult Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)

A Phase 3 Randomized Double-Blind Placebo-Controlled Study 

A Phase 2 Study to Evaluate the Safety and Tolerability of IMR-687 in Subjects with Beta Thalassemia

A Pivotal, Open-Label, Multicenter Study to Assess the Efficacy and Safety of BIVV009 in Patients with Primary Cold Agglutinin Disease who have a Recent History of Blood Transfusion

A Phase 3 Randomized Double-Blind Placebo-Controlled Study Investigating the Efficacy and Safety of Roxadustat (FG-4592) for Treatment of Anemia in Patients with Lower Risk Myelodysplastic Syndrome (MDS) with Low Red Blood Cell (RBC) Transfusion Burden (LTB).

A Phase 2, Multi-Center, Open Label, Simon Two-Stage Study to Evaluate the Safety and Efficacy of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia.

A Randomized, Double-Blind, Placebo-Controlled Studyof BIVV009 A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of BIVV009 in Patients with Primary Cold Agglutinin Disease Without a Recent History of Blood Transfusion

Phase 3,Open-Label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) versus Epoetin Alfa

A Phase 3 Study of ALXN1210 versus Eculizumab in Patients With Paroxysmal Notcurnal Hemoglobinuria.

A Phase Randomized Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Anagrelide in Subjects with Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea.

Phase 3,Open-Label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) versus Epoetin Alfa for the Treatment of Anemia due to IPSS-R very low, low or intermediate risk Myelodysplastic Syndromes (MDS) in ESA naive subjects who require red blood cell transfusions.

An Open-label, Nonrandomized, Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Belinostat in Patients with Relapsed/Refractory Solid Tumors or Hematological Malignancies Who Have Wild-Type, Heterozygous, and Homozygous UGT1A1*28 Genotypes

An Open Label, Prospective, Study to Assess the Safety, Tolerability, Efficacy and Pharmacokinetics of APL-2 in Patients with Warm Antibody Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD).

An Open Label, Prospective, Study to Assess the Safety, Tolerability, Efficacy and Pharmacokinetics of APL-2

A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia.

An Open-Label, Phase 2a/2b Study of KRT-232 in Subjects With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PV-MF), Or Post–Essential Thrombocythemia MF (Post–ET-MF) Who Have Failed Ruxolitinib.

An Open Label, Prospective, Study to Assess the Safety, Tolerability, Efficacy and Pharmacokinetics of APL-2 in Patients with Warm Antibody Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD).

Randomized, Double-Blind, Phase 3 Study to Evaluate the Activity of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic, Anemic Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera (PV), Myelofibrosis, or Post Essential Thrombocythemia (ET) Myelofibrosis who were Previously Treated with JAK Inhibitor Therapy

An Open-Label, Phase 2a/2b Study of KRT-232 in Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post-ET-MF) Who Have Failed Ruxolitinib.

An Open-Label, Phase 2a/2b Study of KRT-232 in Subjects With Primary Myelofibrosis (PMF)

A Phase 2, Multi-Center, Open Label, Simon Two-Stage Study to Evaluate the Safety and Efficacy of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

A Multi-Center, Open-Label, Two-Period Cross-Over, Patient -Pilot Study DisperSol to Evaluate the Safety, Tolerability, Pharmacokinetics and Iron Chelating Activity of DST-0509 (Deferasirox ) Tablets in Thalassemia Patients with Inadequate Response to Standard Chelation Therapy.

An Open-Label, Phase 2a/2b Study of KRT-232 in Subjects With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PV-MF), Or Post–Essential Thrombocythemia MF (Post–ET-MF) Who Have Failed Ruxolitinib.

A Single Arm Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Patients with Atypical Hemolytic Uremic Syndrome (aHUS)

A Multi-Center, Open-Label, Two-Period Cross-Over, Patient -Pilot Study DisperSol DST-0509-201

A Two-Part, Randomized, Open-label, Multicenter, Phase 2a/2b Study of the Efficacy, Safety, and Pharmacokinetics of KRT-232

A Two-Part, Randomized, Open-label, Multicenter, Phase 2a/2b Study of the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared to Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemia Vera. (SPONSOR IS PROVIDING: KRT-232) .

Phase 3,Open-Label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) versus Epoetin Alfa for the Treatment of Anemia due to IPSS-R very low, low or intermediate risk Myelodysplastic Syndromes (MDS) in ESA naive subjects who require red blood cell transfusions.

A Two-Part, Randomized, Open-label, Multicenter, Phase 2a/2b Study of the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared to Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemia Vera.

An Open-Label, Phase 2a/2b Study of KRT-232 in Subjects With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PV-MF), Or Post–Essential Thrombocythemia MF (Post–ET-MF) Who Have Failed JAK2 Inhibitor. (SPONSOR IS PROVIDING: KRT-232)

Phase 3,Open-Label, Randomized Study ACE-536-MDS-002

Phase 1, Dose-Escalation and Cohort Expansion Study of Intravenous CBL0137 in Subjects with Previously Treated Hematological Cancers.

Phase 3,Open-Label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) versus Epoetin Alfa for the Treatment of Anemia due to IPSS-R very low, low or intermediate risk Myelodysplastic Syndromes (MDS) in ESA naive subjects who require red blood cell transfusions.

A Phase 3,Open-Label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) versus Epoetin Alfa for the Treatment of Anemia due to IPSS-R very low, low or intermediate risk Myelodysplastic Syndromes (MDS) in ESA naive subjects who require red blood cell transfusions.

A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia.

A Phase III Open-label, Comparative Safety and Efficacy Trial of Intravenous Iron Isomaltoside (Monofer®) and Iron Sucrose in Subjects with Iron Deficiency Anemia who are Intolerant or Unresponsive to Oral Iron Therapy or in whom the Hemoglobin Measurement in Investigators' Opinion were Sufficiently low as to Require Rapid Repletion of Iron Stores to Minimize the Risk of Receiving a Blood Transfusion.

A Two-Part, Randomized, Open-label, Multicenter, Phase 2a/2b Study of the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared to Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemia Vera.

Efficacy and Safety of M281 in Adults with Warm Autoimmune Hemolytic Anemia

A Phase 3 Randomized Double-Blind Placebo-Controlled Study Investigating the Efficacy and Safety of Roxadustat (FG-4592) for Treatment of Anemia in Patients with Lower Risk Myelodysplastic Syndrome (MDS) with Low Red Blood Cell (RBC) Transfusion Burden (LTB) (Opened 10/23/2017) (Roxadustat (FG-4592) will be provided by the trial)

A Multi-Center, Open-Label, Two-Period Cross-Over, Patient -Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Iron Chelating Activity of DST-0509 (Deferasirox ) Tablets in Thalassemia Patients with Inadequate Response to Standard Chelation Therapy.

Efficacy and Safety of M281 in Adults with Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double-blind, Placebo-controlled Study.


Lung

A Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) versus Cyclophosphomide (CTX), Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients with Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line

A Phase 3 Study of Rovalpituzumab Tesirine Compared with Topotecan for Subjects with Advanced or Metastatic DLL3 high Small Cell Lung Cancer (SCLC) who have First Disease Progression During or Following Front-Line Platinum-Based Chemotherapy.

A phase 3 Randomized Open-label Study of Brigatinib ( ALUNBRIG) Versus Alectinib (ALECENSA) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI), 2ND LINE OR GREATER METASTATIC.

A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer

A phase 3, Randomized, Double Blind Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of Anamorelin HCL for the Treatment of Malignancy Associated Weight Loss And Anorexia in Adult patients with Advanced Non-Small Cell Lung Cancer, 2ND line or greater metastatic.

A phase 3, Randomized, Double Blind Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of Anamorelin HCL for the Treatment of Malignancy Associated Weight Loss And Anorexia in Adult patients with Advanced Non-Small Cell Lung Cancer.

Randomized, Single Blinded Phase 3 Study of Second- or Third-Line Chemotherapy with Docetaxel + Plinabulin Compared to Docetaxel + placebo in Patients with Advanced Non-Small Cell Lung Cancer with at least one measurable lung lesion

A Phase Ib Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined with Pembrolizumab in Subjects with Selected Hyaluronan-High Solid Tumors.

A phase 3, Randomized, Double Blind Placebo-Controlled Multicenter Study ANAM-17-20

A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy, 2nd Line.

An Open-Label, Phase 2, Parallel Arm Study to Evaluate the Safety, Tolerability, and Activity of TAK-931

A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy

An Open-Label, Phase 2, Parallel Arm Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 Single Agent in Patients With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors, 2ND LINE.

An Open-label, Randomized Phase 3 Efficacy Study of ASP8273 vs Erlotinib or Gefitinib in First-line Treatment of Patients with Stage IIIB/IV Non-small Cell Lung Cancer Tumors with EGFR Activating Mutations

A Randomized, Single Blinded Phase 3 Study of Second- or Third-Line Chemotherapy with Docetaxel + Plinabulin Compared to Docetaxel + placebo in Patients with Advanced Non-Small Cell Lung Cancer with at least one measurable lung lesion.

A phase 3, Randomized, Double Blind Placebo-Controlled Multicenter Study to evaluate the Efficacy and Safety of Anamorelin HCL for the Treatment of Malignancy Associated Weight Loss And Anorexia in Adult patients with Advanced Non-Small Cell Lung Cancer, 2ND LINE OR GREATER METASTATIC.

A Phase 2, Multi-Arm Study of Niraparib Administered Alone and in Combination with Pembrolizumab in Patients with Non-Small Cell Lung Cancer, 1ST line metastatic.

An Open-Label, Phase 2, Parallel Arm Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 Single Agent in Patients With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors, 2ND line or greater metastatic.

A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy

A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 (AP32788) in Non-Small Cell Lung Cancer, 2ND LINE.

A Randomized, Single Blinded Phase 3 Study of Second- or Third-Line Chemotherapy with Docetaxel + Plinabulin Compared to Docetaxel + placebo in Patients with Advanced Non-Small Cell Lung Cancer with at least one measurable lung lesion

A Randomized Phase 2 Trial of AM0010 in Combination with Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1.

A phase 3, Randomized, Double Blind Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of Anamorelin HCL for the Treatment of Malignancy Associated Weight Loss And Anorexia in Adult patients with Advanced Non-Small Cell Lung Cancer, 3RD LINE.

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C

Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields)

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (AMBER)

An Open-Label, Phase 2, Parallel Arm Study to Evaluate the Safety, Tolerability, and activity of TAK-931 Single Agent in Patients with Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors, 2ND LINE.

A Safety and Pharmacokinetic Study of G1T28 in Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer (SCLC) Receiving Topotecan Chemotherapy

A Randomized Phase 2 Trial of AM0010 in Combination with Pembrolizumab vs. Pembrolizumab

A Randomized, Double Blind, Phase 3 Study of Platinum-Based Chemotherapy With or Without INCMGA00012 in First-Line Metastatic Squamous and Nonsquamous Non–Small Cell Lung Cancer

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications, 1ST line metastatic.

Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) concurrent with standard of care therapies for treatment of stage 4 non-small cell lung cancer (NSCLC) following platinum failure, 2ND line or greater metastatic.

A Randomized, Single Blinded Phase 3 Study of Second- or Third-Line Chemotherapy with Docetaxel + Plinabulin Compared to Docetaxel + placebo in Patients with Advanced Non-Small Cell Lung Cancer with at least one measurable lung lesion ( Opened 1/30/2017)  (Plinabulin is provided by the trial)

A phase 3, Randomized, Double Blind Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of Anamorelin HCL for the Treatment of Malignancy Associated Weight Loss And Anorexia in Adult patients with Advanced Non-Small Cell Lung Cancer.

A Phase 3 Multicenter Open-label Study of Brigatinib versus Crizotinib AP26113-13-301 in Patients with ALK-positive Advanced Lung Cancer.

Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib.

A Phase 2, Open Label Study to Evaluate Safety And Clinical Activity of Avelumab (Bavencio) In Combination With Acitinib (Inlyta) in patients with advanced or metastatic previously treated Non-Small Cell Lung Cancer or Treatment Naive Cisplatin Ineligible Urothelial Cancer.

A Phase IIIb/IV Safety and Efficacy Trial of Flat Dose Nivolumab in Combination with Ipilimumab

A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel

A Phase 2/3, Multicenter, Randomized, Double Blind Study to Evaluate Duration of Severe Neutropenia with Plinabulin Versus Pegfilgrastim in Patients with Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy

rospective, Interventional Pilot Study of Mobile Devices and Digital Applications to Detect Early Pneumonitis and Other Pulmonary Adverse

Events in Unresectable Stage III Non-Small Cell Lung Cancer Patients on Durvalumab (Observational study)

A Phase 2, Open Label Study to Evaluate Safety And Clinical Activity of Avelumab

A Randomized Phase 2 Trial of AM0010 in Combination with Pembrolizumab vs. Pembrolizumab Alone as First-line Therapy in Patients with Metastatic Non-Small Cell Lung Cancer whose Tumors Have High PD-L1 Expression, 1ST LINE METASTATIC.

Treatment Resistant Following Anti-Cancer Therapies (Translate) (Opened 2/23/19)

A Phase IIIb/IV Safety and Efficacy Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer, 1ST line metastatic.

A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy, 2ND line or greater metastatic.

Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non–Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib

A Phase 2/3, Multicenter, Randomized, Double Blind Study to Evaluate Duration of Severe Neutropenia with Plinabulin Versus Pegfilgrastim in Patients with Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy

A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination with AB122, and AB154 in Combination with AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer

A Phase 2/3, Multicenter, Randomized, Double Blind, Study to Evaluate Duration of Severe Neutropenia with Plinabulin Versus Pegfilgrastim

A Phase IIIb/IV Safety and Efficacy Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer, 1ST LINE METASTATIC.

Blood Sample Collection to Evaluate Biomakers in Subjects with Untreated Solid Tumors, 1ST line metastatic.

A phase 3, Randomized, Double Blind Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of Anamorelin HCL

A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIGTM) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

A multicenter, randomized, double-blind Phase III trial to evaluate efficacy and safety of BI 695502 plus chemotherapy versus Avastin® plus chemotherapy in patients with advanced nonsquamous Non-Small Cell Lung Cancer.

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1- 1st line metastatic.

A Phase 2/3, Multicenter, Randomized, Double Blind, Study to Evaluate Duration of Severe Neutropenia with Plinabulin Versus Pegfilgrastim in Patients with Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy, 2ND LINE OR GREATER METASTATIC.

Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated Solid Tumors.

Treatment Resistant Following Anti-Cancer Therapies, 1ST line metastatic.

A phase 3, Randomized, Double Blind Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of Anamorelin HCL for the Treatment of Malignancy Associated Weight Loss And Anorexia in Adult patients with Advanced Non-Small Cell Lung Cancer, 3RD line.

A phase 3, Randomized, Double Blind Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of Anamorelin HCL for the Treatment of Malignancy Associated Weight Loss And Anorexia in Adult patients with Advanced Non-Small Cell Lung Cancer.

A Phase 2 trial of MGCD265 in patients with locally advanced, unresectable or metastatic non-small cell lung cancer (NSCLC) that has activating genetic changes of the MET gene.

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors- 2nd line or greater metastatic.

A randomized, open-label study of combinations of standard and high dose regn2810 (cemiplimab; anti-pd-1antibody) and ipilimumab (anti-ctla-4 antibody) in the second-line treatment of patients with metastatic non-small cell lung cancer with tumors expressing pdl10-100%, 2ND LINE OR GREATER METASTATIC.

Treatment-Resistant Following Anti-Cancer Therapies.

A Pilot, Open-Label, Multi-Center, Multi-Dose Study of GRN-1201

An Open-Label, Phase 2, Parallel Arm Study to Evaluate the Safety, Tolerability, and Activity of TAK-931

Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) concurrent with standard of care therapies for treatment of stage 4 non-small cell lung cancer (NSCLC) following platinum failure.

An Open-label, Randomized Phase 3 Efficacy Study of ASP8273 vs Erlotinib or Gefitinib in First-line Treatment of Patients with Stage IIIB/IV Non-small Cell Lung Cancer Tumors with EGFR Activating Mutations.

A Randomized, Phase 3, Open-Label Study of 2810ONC-16113

A Phase 2, Multi-Arm Study of Niraparib Administered Alone and in Combination with Pembrolizumab in Patients with Non-Small Cell Lung Cancer. 1ST line metastatic.

A Pilot, Open-Label, Multi-Center, Multi-Dose Study of GRN-1201 Added to Pembrolizumab in Subjects with Non-Small Cell Lung Cancer with High PD-L1 Expression.

A Pilot, Open-Label, Multi-Center, Multi-Dose Study of GRN-1201 Added to Pembrolizumab in Subjects with Non-Small Cell Lung Cancer with High PD-L1 Expression, 1ST line metastatic.

An Open-Label, Phase 2, Parallel Arm Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 Single Agent in Patients With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors, 3RD line.

A Phase 2 MuLticenter, Open-label Study of Rucaparib as Treatment for SoliD Tumors Associated with DEleteriouS MuTations in Homologous RecombinAtion Repair Genes

A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination with Tremelimumab in Subjects with Advanced Non-Small Cell Lung Cancer.

A Two-Part, Open-Label, Randomized, Phase II/III Study of Dinutuximab and Irinotecan versus Irinotecan for Second Line Treatment of Subjects with Relapsed or Refractory 2ND LINE METASTATIC Small Cell Lung Cancer (SCLC).

A Randomized, Phase 3, Open-Label Study of 2810ONC-16111

An Open-Label, Phase 2, Parallel Arm Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 Single Agent in Patients With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors, 2ND LINE OR GREATER METASTATIC.

A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies, 2ND line or greater metastatic.

Phase 1/2, study of pegzilarginase 

A phase 3, Randomized, Double Blind Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of Anamorelin HCL for the Treatment of Malignancy Associated Weight Loss And Anorexia in Adult patients with Advanced Non-Small Cell Lung Cancer.

A Randomised, Parallel, Double Blinded Study to Compare the Efficacy and Safety of FKB238 to Avastin® In 1st Line Treatment for Patients with Advanced/Recurrent Non-Squamous Non-Small Cell Lung Cancer in Combination of Paclitaxel and Carboplatin

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (anti-PD-1 antibody), Ipilimumab (anti-CTLA4 antibody), and Platinum-based doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50 %, 1ST LINE METASTATIC.

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Iipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in First-Line Treatment of Patients With Advanced or Metastatic Non-Small Cell Lung Cancer With Tumors Expressing PD-L1 ≥50%, 1ST LINE METASTATIC.

A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 (AP32788) in Non-Small Cell Lung Cancer, 2ND LINE OR GREATER METASTATIC.

Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+)

Phase 1/2, study of pegzilarginase (AEB1102, Co-ArgI-PEG) in combination with pembrolizumab in the treatment of patients with extensive disease (ED) small cell lung cancer (SCLC), 2nd line metastatic.

A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy

A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies.

A Phase 1 Dose Escalation and Phase 2 Randomized, Open-Label Study of Nivolumab and Veliparib in Combination with Platinum Doublet Chemotherapy in Subjects with Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC).

A phase 3, Randomized, Double Blind Placebo-Controlled Multicenter Study Helsinn-ANAM-17-20

A pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) concurrent with a standard of care therapies for the treatment of stage 4 non-small cell lung cancer (NSCLC) following platinum failure, 2ND LINE OR GREATER METASTATIC.

Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non–Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib, 2ND line or greater metastatic.

A phase 3, Randomized, Double Blind Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of Anamorelin HCL for the Treatment of Malignancy Associated Weight Loss And Anorexia in Adult patients with Advanced Non-Small Cell Lung Cancer.

A Phase 2 MuLticenter, Open-label Study of Rucaparib as Treatment for SoliD Tumors Associated with DEleteriouS MuTations in Homologous RecombinAtion Repair Genes

An Open-Label Phase 1/2 Study of INCB039110 in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer.

A phase 3, Randomized, Double Blind Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of Anamorelin HCL for the Treatment of Malignancy Associated Weight Loss And Anorexia in Adult patients with Advanced Non-Small Cell Lung Cancer, 1ST LINE METASTATIC.

A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy, 2ND LINE OR GREATER METASTATIC.


Lymphoma

Open-label, Single-Arm, Phase 2 Study of Oral HDAC-inhibitor Abexinostat in Patients with Relapsed or Refractory Follicular Lymphoma.

A Phase Ib, Multicenter, Open-Label Study of ACP-196 in Combination with Bendamustine and Rituximab (BR) in Subjects with Mantle Cell Lymphoma.

A Phase 3 Randomized, Double-Blind Study of PF-05280586 versus Rituximab for the First-Line Treatment of Patients with CD20-positive, Low Tumor Burden, Follicular Lymphoma.

A Phase 3 Randomized, Double-Blind Study of PF-05280586 versus Rituximab for the First-Line Treatment of Patients with CD20-positive, Low Tumor Burden, Follicular Lymphoma

A Phase Ib, Multicenter, Open-Label Study of ACP-196 in Combination with Bendamustine and Rituximab (BR) in Subjects with Mantle Cell Lymphoma

Phase 1, Dose-Escalation and Cohort Expansion Study of Intravenous CBL0137 in Subjects with Previously Treated Hematological Cancers, 2ND LINE.

Open-label, Single-Arm, Phase 2 Study of Oral HDAC-inhibitor Abexinostat in Patients with Relapsed or Refractory Follicular Lymphoma.

Phase 1, Dose-Escalation and Cohort Expansion Study of Intravenous CBL0137

Phase 1, Dose-Escalation and Cohort Expansion Study of Intravenous CBL0137 in Subjects with Previously Treated Hematological Cancers 2ND line.

A Multi-Center,Randomized Double-Blind,Placebo-Controlled,Two-Arm Phase 2 Study of ME-401 in subjects with Follicular Lymphoma After Failure of Two or More Prior Systemic Therapies.

A Multi-Center,Randomized Double-Blind,Placebo-Controlled,Two-Arm Phase 2 Study of ME-401 in subjects with Follicular Lymphoma After Failure of Two or More Prior Systemic Therapies.

A Phase IIb, randomized, double-blind, placebo-controlled, low-dose cytarabine and Lintuzumab In comparison with the low-dose cytarabine and placebo in patients 60 years of age and older with previously untreated AML.

Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY 80-6946 in Patients with Relapsed, Indolent or Aggressive Non-Hodgkin’s Lymphomas.

A Randomized, Open Label, Phase 2 Study of Rituximab and Bendamustine with or without Brentuximab Vedotin for Relapsed or Refractory CD30-Positive Diffuse Large B-Cell Lymphoma.


MDS

2 randomized phase study comparing two doses lists Ezatiostat Hydrochloride (TELINTRA, TLK199 Tablets) in low to intermediate-1 risk myelodysplastic syndrome (MDS).


Multiple Myeloma

A Single Arm, Open-Label, Phase 2 Study of Melflufen in Combination with Dexamethasone in Patiets with Relapsed Refractory Multiple Myeloma who are Refractory to Pomalidomide and/or Daratumumab, 2ND/3rd Line.

A Phase 2 Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination with Carfilzomib and Dexamethasone (DKd) Compared with BMSCarfilzomib and Dexamethasone (Kd) in Participants with Multiple Myeloma who have been Previously Treated with Daratumumab Intravenous (Dara-IV) to Evaluate Daratumumab Retreatment.

A Phase 3 Study Comparing Daratumumab, VELCADE (Bortezomib ), Lenalidomide, and Dexamethasone ( D-VRd) with VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects with Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy, 1st LINE.

A Prospective, Multinational Study of Real-Life Current Standards of Care in Patients with Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including PI, IMiD, and CD38 Monoclonal Antibody Treatment

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO) in Combination with Lenalidomide and Dexamethasone (IRD) in Patients with Multiple Myeloma Previously Receiving a Bortezomib-Based Induction Regimen.

Prospective Research Assessment in Multiple Myeloma: An Observational tgEvaluation (PREAMBLE) (Open 5/10/2013)

A Phase 2 Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination with Carfilzomib and Dexamethasone (DKd) Compared with Carfilzomib and Dexamethasone (Kd) in Participants with Multiple Myeloma who have been Previously Treated with Daratumumab Intravenous (Dara-IV) to Evaluate Daratumumab Retreatment, 2ND/3rd Line.

A Disease Registry Encompassing the Care Of patients with Multiple Myeloma on panobinostat (RECOMM)

Phase 1, Dose-Escalation and Cohort Expansion Study of Intravenous CBL0137 in Subjects with Previously Treated Hematological Cancers.

A Single Arm, Open-Label, Phase 2 Study of Melflufen in Combination with Dexamethasone in Patients with Relapsed Refractory Multiple Myeloma who are Refractory to Pomalidomide and/or Daratumumab. (Open 11/2/2018) (Melflufen is provided by trial)

A Prospective, Multinational Study of Real-Life Current Standards of Care in Patients with Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including PI, IMiD, and CD38 Monoclonal Antibody Treatment

A Phase 2 Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination with Carfilzomib and Dexamethasone (DKd) Compared with Carfilzomib and Dexamethasone (Kd) in Participants with Multiple Myeloma who have been Previously Treated with Daratumumab Intravenous (Dara-IV) to Evaluate Daratumumab Retreatment.

Phase 3 Study Comparing Daratumumab, VELCADE (Bortezomib)

Phase 3 Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone ( D-VRd) with VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects with Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy, 1st line.

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination with Lenalidomide and Dexamethasone (IRD)

A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk Smoldering Multiple Myeloma.

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination with Lenalidomide and Dexamethasone (IRD) in Patients with Multiple Myeloma Previously Receiving a Bortezomib-Based Induction Regimen.

Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation.

Phase 1, Dose-Escalation and Cohort Expansion Study of Intravenous CBL0137

A Prospective Reseach Assessment in Multiple Myeloma: An Observational Evaluation.

Phase 1, Dose-Escalation and Cohort Expansion Study of Intravenous CBL0137 in Subjects with Previously Treated Hematological Cancers, 2ND/3rd line.

A Single Arm, Open-Label, Phase 2 Study of Melflufen in Combination with Dexamethasone in Patiets with Relapsed Refractory Multiple Myeloma who are Refractory to Pomalidomide and/or Daratumumab. 2ND/3rd Line

A Single Arm, Open-Label, Phase 2 Study of Melflufen in Combination with Dexamethasone in Patients with Relapsed Refractory Multiple Myeloma who are Refractory to Pomalidomide and/or Daratumumab, 2ND/3rd line.

A Single Arm, Open-Label, Phase 2 Study of AB OP-106

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination with Lenalidomide and Dexamethasone (IRD) in Patients with Multiple Myeloma Previously Receiving a Bortezomib-Based Induction Regimen

Directed Bone Marker Dosage Zometa (zoledronic acid) for the prevention of bone complications in patients with advanced multiple myeloma.

Factors determining overall survival in patients with multiple myeloma treated with Zoledronic Acid.

A Phase II Study of Pegylated Liposomal Doxorubicin, Bortezomib and Dexamethasone (DVD) for newly diagnosed patients and multiple myeloma.

Randomized Phase IIIb of three treatment regimens in patients with previously untreated multiple myeloma who are not considered candidates for high-dose chemotherapy and autologous stem cell transplantation: VELCADE (bortezomib), thalidomide dexamethasone (VTD) versus VELCADE and dexamethasone (VD) compared to VELCADE, melphalan and prednisone (VMP).

Prospective Evaluation of Research in Multiple Myeloma: an observational evaluation (Preamble).

An Observational Evaluation.

A Phase 2, Multicenter, Single-Arm, Open-Label Study of Pomalidomide in Combination with Low-Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide Plus Dexamethasone in the Second-Line Setting.

A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High Dose Therapy.

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination with Lenalidomide and Dexamethasone in Subjects with Multiple Myeloma.


Nausea and Vomiting

Multicenter phase III, randomized, double-blind, double-dummy, parallel group active in the efficacy and safety of oral Netupitant control is given in combination with palonosetron and dexamethasone compared to palonosetron and oral dexamethasone for the prevention of nausea and vomiting in cancer patients with chemotherapy emetogenic Receivingmoderately.

A phase 3, multicenter, randomized, double-blind, active-controlled safety and efficacy of Rolapitant for the Prevention of chemotherapy nausea and vomiting induced by chemotherapy (CINV) in patients receiving highly emetogenic chemotherapy (HEC).

A phase 3, multicenter, randomized, double-blind, active-controlled safety and efficacy of Rolapitant for the Prevention of chemotherapy nausea and vomiting induced by chemotherapy (CINV) in patients receiving moderately emetogenic chemotherapy (MEC).


Ovarian

A phase 1/2 Study of Galinpepimut-s in Combination with Pembrolizumab (MK-3475) in Patients with Selected Advanced Cancers.

A Phase 2 MuLticenter, Open-label Study of Rucaparib as Treatment for SoliD Tumors Associated with DEleteriouS MuTations in Homologous RecombinAtion Repair Genes

A Phase 2 MuLticenter, Open-label Study of Rucaparib as Treatment for SoliD Tumors Associated with DEleteriouS MuTations in Homologous RecombinAtion Repair Genes

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation.

A Study of Physician’s Choice Chemotherapy Weekly Paclitaxel (PCC) or Pegylated Liposomal Doxorubicin (PLD) Plus Bevacizumab and CA4P versus PCC Plus Bevacizumab and Placebo for Subjects with Platinum Resistant, Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer.

A Phase 1/2a Evaluation of the Safety and Efficacy of Adding AL3818, a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy in Subjects with Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma.

Blood Sample Collection to Evaluate Biomakers in Subjects with Untreated Solid Tumors, 1st LINE.

Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated Solid Tumors, 1st LINE.

A Phase I/II Study Evaluating the Dosing, Safety, Efficacy, and Biological Activity of Intraperitoneal GEN-1 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) Administered in Combination with Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed with Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer, 1st LINE.

A phase 1/2 Study of Galinpepimut-s in Combination with Pembrolizumab (MK-3475) in Patients with Selected Advanced Cancers, 2nd/ 3rd Line.

Blood Sample Collection to Evaluate Biomakers in Subjects with Untreated Solid tumors, 1st line.

A Phase I/II study Evaluating the Dosing, Safety,Efficacy, and Biological Activity of Intraperitoneal GEN-1 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) Administered in Combination with Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed with Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. 

Phase IIb study evaluate the safety and efficacy of TXA127 in reducing the incidence and severity of thrombocytopenia in patients receiving combination therapy of gemcitabine and platinum per ovary, fallopian tube or peritoneal carcinoma.

Randomized phase II trial Investigate liposomal doxorubicin with or without anti-derived growth factor platelet receptor alpha (PDGFR) monoclonal antibody IMC-3G3.

An open-label randomized crossover bioequivalence study and safety of doxorubicin hydrochloride injection liposome formulations in patients with advanced ovarian carcinoma.

A double-blind, randomized, placebo-controlled HVAC (Augologous dendritic cells pulsed with recombinant human fusion protein [mucin 1-glutathione S-Transferqase] Along with rusty polymannose) as maintenance therapy in patients with epithelial ovarian Cancer (EOC) in complete remission after first-line chemotherapy.

A Phase 1/2a Evaluation of the Safety and Efficacy of AL3818 to Standard Platinum Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Cancer.


Pancreatic

A Phase III Multicenter Open-Label Randomized Trial to Evaluate Efficacy and Safety of FOLFIRINOX (FFX) versus Combination of CPI-613 with modified FOLFIRINOX (mFFX) in Patients with Metastatic Adenocarcinoma of the Pancreas, 1ST line.

A Phase 2, Open-Label, Randomized Study to Assess the Antitumor Activity and Safety of Zolbetuximab (IMAB362) in Combination with Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects with Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma.

Blood Sample Collection to Evaluate Biomakers in Subjects with Untreated Solid Tumors, 1st line.

A Phase III Multicenter Open-Label Randomized Trial to Evaluate Efficacy and Safety of FOLFIRINOX

A Phase III Multicenter Open-Label Randomized Trial to Evaluate Efficacy and Safety of FOLFIRINOX (FFX) versus Combination of CPI-613 with modified FOLFIRINOX (mFFX) in Patients with Metastatic Adenocarcinoma of the Pancreas, 1st line.

A Phase 2, Open-Label, Randomized Study to Assess the Antitumor Activity and Safety of Zolbetuximab

A Phase 2, Open-Label, Randomized Study to Assess the Antitumor Activity and Safety of Zolbetuximab (IMAB362) in Combination with Nab-Paclitaxel and Gemcitabine (Nab-P +GEM) as First Line Treatment in Subjects with Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma, 1st line.

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus nab-Paclitaxel and Gemcitabine in Subjects with Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma, 1st line metastatic.

A Randomized Phase 3 Study of the Efficacy and Safety of Glufosfamide

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus nab-Paclitaxel and Gemcitabine in Subjects with Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma.

A Randomized Phase 3 Study of the Efficacy and Safety of Glufosfamide Compared with Fluorouracil (5-FU) in Patients with Metastatic Pancreatic Adenocarcinoma Previously Treated with Gemcitabine, 2nd line metastatic.

A Randomized Phase 3 Study of the Efficacy and Safety of Glufosfamide Compared with Fluorouracil in Patients with Metastatic Pancreatic Adenocarcinoma Previously Treated with Gemcitabine -2ND LINE METASTATIC.

Blood Sample Collection to Evaluate Biomakers in Subjects with Untreated Solid Tumors.

Blood Sample Collection to Evaluate Biomakers in Subjects with Untreated Solid Tumors, 1st LINE.

A Phase 2 MuLticenter, Open-label Study of Rucaparib as Treatment for SoliD Tumors Associated with DEleteriouS MuTations in Homologous RecombinAtion Repair Genes.

A Phase III Multicenter Open-Label Randomized Trial to Evaluate Efficacy and Safety of FOLFIRINOX (FFX) versus Combination of CPI-613

A Randomized Phase 3 Study of the Efficacy and Safety of Glufosfamide Compared with Fluorouracil (5-FU) in Patients with Metastatic Pancreatic Adenocarcinoma Previously Treated with Gemcitabine (Open 1/21/2014) (Glufosfamide is provided by the trial)

A, open, randomized, phase 2 trial of gemcitabine with or without Bavituximab in patients with pancreatic cancer in previously untreated stage IV.

A Randomized Phase 2 Study of Efficacy and Safety Ruxolitinib in combination with capecitabine for patients with recurrent or refractory treatment of metastatic pancreatic cancer.

A randomized Security and exploratory efficacy study of Kanglaite injection Gemcitabine Plus (G + K) versus gemcitabine in patients with advanced pancreatic cancer.

A Randomized Phase 3 Study of the Efficacy and Safety of Glufosfamide Compared with Fluorouracil (5-FU) in Patients with Metastatic Pancreatic Adenocarcinoma Previously Treated with Gemcitabine).

Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor, Ruxolitinib or Placebo in Combination with Capecitabine in Subjects with Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 1 Study).

A Phase 2, Randomized, Multicenter Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase) Combined with nab-Paclitaxel Plus Gemcitabine Compared With nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Previously Untreated Pancreatic Cancer.

A Phase III, Randomized, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients with gBRCA Mutated Metastatic Pancreatic Cancer whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy.


Prostate

A Phase 2 MuLticenter, Open-label Study of Rucaparib as Treatment for SoliD Tumors Associated with DEleteriouS MuTations in Homologous RecombinAtion Repair Genes

A Randomized, Open-Label, Active-Controlled, Multi-Center Study to Evaluate the Serum Testosterone Level in Patients with Metastatic Castration-Resistant Prostate Cancer on SoluMatrix™ Abiraterone Acetate 500mg (4 x 125mg QD) with Methylprednisolone (4mg BID) as Compared to Zytiga® (4 x 250mg QD) with Prednisone (5mg BID).

Randomized, Double Blind, Multicenter, Parallel-Group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men with Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy

A Multi-Center, Randomized, Assessor-Blind, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Events (MACEs) in Patients with Prostate Cancer and Cardiovascular Disease Receiving Degarelix (GnRH Receptor Antagonist) or Leuprolide (GnRH Receptor Agonist).

Blood Sample Collection to Evaluate Biomakers in Subjects with Untreated Solid Tumors, 1st LINE

Ferring Pharmaceuticals 000108 study: A Multi-Center, Randomized, Assessor-Blind, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Events (MACEs) in Patients with Prostate Cancer and Cardiovascular Disease Receiving Degarelix (GnRH Receptor Antagonist) or Leuprolide (GnRH Receptor Agonist), 1st LINE.

Treatment-Resistant Following Anti-Cancer Therapies (Translate), 1st LINE.

Pfizer A9001502: Treatment Resistant Following Anti-Cancer Therapies, 1st line.

A Phase 2/3, Multicenter, Randomized, Double Blind Study to Evaluate Duration of Severe Neutropenia with Plinabulin Versus Pegfilgrastim in Patients with Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy

Treatment Resistant Following Anti-Cancer Therapies (Translate) - Castrate Resistant prostate CA.

Asymptomatic castration resistant prostate cancer (CRPC) metastatic - Phase II randomized, double-blind, placebo-controlled trial to determine the efficacy and safety of ABR-215050 in asymptomatic patients with metastatic prostate cancer resistant castration.

A Randomized, Double - Blind, Multicenter Study denosumab compared with zoledronic acid (Zometa) in the treatment of bone metastases in men with hormone-refractory prostate cancer.

Prospective observational study of Survival, treatment patterns, disease and economic outcomes in patients with refractory metastatic to cancer castration prostate (CRPC) with progression during or after first - line docetaxel - based regime.

A randomized phase III study comparing standard first-line docetaxel / prednisone docetaxel / prednisone in combination with custirsen (OGX-011) in men with metastatic prostate cancer resistant to castration.

Randomized, Double Blind, Multicenter, Parallel-Group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men with Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy.


Renal Cell Carcinoma

A Randomized: Double-blind, Phase 2 Trial to Assess Safety and Efficacy of Lenvatinib at Two Different Starting Doses (18 mg vs. 14 mg QD) in Combination with Everolimus (5 mg QD) in Renal Cell Carcinoma Following One Prior VEGF-Targeted Treatment.

A Phase 3 Randomized Open Label Study 17-214-09

A Phase 3 Randomized Open Label Study to Compare NKTR-214 Combined with Nivolumab to the Investigator's Choice of Sunitinib or Carbozantinib in Patients with Previously Advanced Renal Cell Carcinoma, 1st line.

Treatment-Resistant Following Anti-Cancer Therapies (Translate), 1st line.

Treatment-Resistant Following Anti-Cancer Therapies, 2ND LINE.

Treatment Resistant Following Anti-Cancer Therapies, 1st line.

A Randomized: Double-blind, Phase 2 Trial to Assess Safety and Efficacy of Lenvatinib

A Randomized: Double-blind, Phase 2 Trial to Assess Safety and Efficacy of Lenvatinib at Two Different Starting Doses (18 mg vs. 14 mg QD) in Combination with Everolimus (5 mg QD) in Renal Cell Carcinoma Following One Prior VEGF-Targeted Treatment, 2ND line.

Treatment Resistant Following Anti-Cancer Therapies, 2ND line.

A Phase 3 Randomized Open Label Study to Compare NKTR-214 Combined with Nivolumab to the Investigator's Choice of Sunitinib or Carbozantinib in Patients with Previously Untreated Advanced Renal Cell Carcinoma.

Treatment Resistant Following Anti-Cancer Therapies (Translate)

Treatment Resistant Following Anti-Cancer Therapies (Translate)

A study of pazopanib versus sunitinib in the treatment of patients with renal cell carcinoma locally advanced and / or metastatic.

Axitinib (AG-013736) as a second-line therapy for metastatic renal cell.


Sarcoma

A Phase 1/1b Study of MGCD516

A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies.

A pivotal trial to determine the efficacy and safety of AP23573 when given as maintenance treatment of patients with soft tissue or bone sarcomas metastatic.


Solid Tumors

Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated Solid Tumors, 1st LINE.

An Open-label, Nonrandomized, Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Belinostat in Patients with Relapsed/Refractory Solid Tumors or Hematological Malignancies Who Have Wild-Type, Heterozygous, and Homozygous UGT1A1*28 Genotypes 

A Multi-Center, Open-Label, Extension Study to Allow Continued Treatment of Patients Who Have Participated in Spectrum-Sponsored Clinical Studies with Belinostat

A Phase 2 MuLticenter, Open-label Study of Rucaparib as Treatment for SoliD Tumors Associated with DEleteriouS MuTations in Homologous RecombinAtion Repair GenesF

A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination with Capecitabine Tablets in Patients with HER2-Positive Advanced Solid Tumors.

An Open-Label, Nonrandomized, Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Belinostat in Patients with Relapsed/Refractory Solid Tumors or Hematological Malignancies who have Mild, Moderate, and Severe Renal Impairment.

A Phase Ib Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined with Pembrolizumab in Subjects with Selected Hyaluronan-High Solid Tumors.

An Open-Label, Nonrandomized, Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Belinostat in Patients with Relapsed/Refractory Solid Tumors or Hematological Malignancies who have Wild-Type, Heterozygous, and Homozygous UGT1A1*28 Genotypes.

A Phase I, Open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications.

A Phase 1 Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination with Tremelimumab (Anti-CTLA-4 Antibody) in Subjects with Advanced Solid Tumors.

A Phase 2/3, Multicenter, Randomized, Double Blind, Study to Evaluate Duration of Severe Neutropenia with Plinabulin Versus Pegfilgrastim in Patients with Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy.

An Open-Label, Nonrandomized, Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Belinostat in Patients with Relapsed/Refractory Solid Tumors or Hematological Malignancies who have Mild, Moderate, and Severe Renal Impairment.

An Open-Label, Nonrandomized, Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Belinostat in Patients with Relapsed/Refractory Solid Tumors or Hematological Malignancies who have Wild-Type, Heterozygous, and Homozygous UGT1A1*28 Genotypes.

An Open-Label, Nonrandomized, Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Belinostat in Patients with Relapsed/Refractory Solid Tumors or Hematological Malignancies who have Wild-Type, Heterozygous, and Homozygous UGT1A1*28 Genotypes.

Blood Sample Collection to Evaluate Biomakers in Subjects with Untreated Solid Tumors, 1st LINE.

A phase Ib, single arm, open-label clinical trial to evaluate QTc and Drug - Interaction Drug Trastuzumab carboplatin in the presence of docetaxel in patients with HER2-positive metastatic or inoperable locally advanced cancer.

A study to assess the relationship between treatment with cetuximab and corrected QT (QTc) interval changes in patients with advanced solid tumors other than brain tumors A phase 1 study to evaluate the effect of NKTR-102 for injection (ETITRNOTECAN PEGOL) on the QT/QTC interval in patients with advanced OR metastatic solid tumors.

An Open-label, multicenter, extension study of NKTR-102 in subjects previously enrolled in NKTR-102 Studies.

A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Subjects with Advanced Solid Tumors.


Urothelial Malignancies

A Phase 1 Open-Label, Dose-Finding Study Evaluating Safety and Pharmacokinetics of FPA144 in Patients with Advanced Solid Tumors - 2ND line and greater.

A Phase 2 Open Label Study of IMMU-132 in Metastatic Urothelial Cancer after Failure of Platinum-Based Regimen or Anti-PD-1 Based Immunotherapy, 2nd Line.

An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy

An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects with Previously Treated rothelial Cancer (EV-301), 3RD LINE OR LOCALLY ADVANCED OR METASTATIC.

Blood Sample Collection to Evaluate Biomakers in Subjects with Untreated Solid Tumors, 1st LINE.

A Phase 2, Open Label Study of NKTR-214

A Phase 2, Open Label Study of NKTR-214 in Combination with Nivolumab in Cisplatin Ineligible, Locally Advanced or Metastatic Urothelial Cancer, Nektar 18-214-10.

A Phase 2 Open Label Study of IMMU-132

A Phase 2 Open Label Study of IMMU-132 in Metastatic Urothelial Cancer after Failure of Platinum-Based Regimen or Anti-PD-1 Based Immunotherapy, 2nd/3rd LINE.

A Phase 2 Open Label Study of IMMU-132 in Metastatic Urothelial Cancer after Failure of Platinum-Based Regimen or Anti-PD-1 Based Immunotherapy.

A Phase 2 MuLticenter, Open-label Study of Rucaparib as Treatment for SoliD Tumors Associated with DEleteriouS MuTations in Homologous RecombinAtion Repair Genes


Specimen Collection

An Observational Study to Collect Specimens for Future Scientific Research

Specimen Collection from Individuals diagnosed with Late State (Stage III or IV) Non-Small Cell Lung Carcinoma


Denotes Active Clinical Trial.

11480 Brookshire Ave #309
Downey
CA
90241
United States
562-869-1201